ClinicalTrials.gg
TerminatedNCT02432664FIMTRIPUpdated Jul 2, 2017

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ODM-108: in Healthy Male Volunteers

A Phase 1 interventional study of ODM-108 Part I and Placebo Part I in Healthy, sponsored by Orion Corporation, Orion Pharma. Terminated at 1 site in Netherlands. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-02.

Sponsored by Orion Corporation, Orion Pharma · Phase 1, Interventional, and Other

How we know

Why this study was terminated
The study was terminated after the second cohort had completed Part II due complex PK results. There were no safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of the study is to investigate to what extent this new study drug is tolerated in humans.

The study is divided into 3 parts (Part III is optional and may go ahead depending on the results of Parts I and II). The volunteers will only be enrolled to one part of the study. In parts I and II the volunteer will receive active study drug or placebo. In part I the volunteers will receive a single dose of one of the eight planned escalating dose levels.

In part II volunteers will receive 4 planned dose levels based on the results obtained in Part 1 of the study, with the option to include an additional dosing group.

In optional part III the volunteer will receive ODM-108 and an already registered drug so that interactions with other drugs can be studied.

It will be investigated how quickly and to what extent the study drug is absorbed and eliminated from the body (this is called pharmacokinetics). In addition, in parts I and II the effect of the compound on the sensation of pain and on cognition (activities of thinking, understanding, learning, and remembering) will be investigated (this is called pharmacodynamics).

Read the detailed description

This is the first time that this compound is being given to humans.

The study will only take place after it has been approved by the Independent Ethics Committee.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written .
  • Good general health
  • Males between 18 and 55 years (inclusive).
  • (BMI) between 18-30 kg/m2 inclusive
  • Weight 55-95 kg (inclusive).
  • Participants with female partners of must adhere to a proper form of .
  • Subjects with light coloured skin.

Exclusion criteria

Exclusion Criteria:

  • A predictable poor compliance or inability to understand and comply with the protocol , instructions and protocol restrictions or communicate well with the investigator.
  • Vulnerable subjects.
  • Veins unsuitable for repeated venipuncture.
  • Evidence of cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric disease as judged by the investigator.
  • Medical history of relevant psychiatric disorders or evidence of clinically relevant neuropsychiatric disease.
  • Suicidal ideation in the 6 months before screening or current risk of suicide based on the investigators judgement.
  • History of to drugs or .
  • Any condition requiring regular concomitant medication.
  • Intake of any medication that could affect the outcome of the study.
  • History of Alcoholism.
  • Inability to refrain from using nicotine-containing products for 48 h before and during the stay in the study centre.
  • History of drug abuse or positive drug screen.
  • Blood donation or loss of a clinically relevant amount of blood within 2 months before the screening visit.
  • Abnormal 12-lead
  • Heart rate \< 40 bpm or > 100 bpm at screening.
  • Systolic BP \< 90 mmHg or > 140 mmHg, diastolic BP\< 45 mmHg or > 90 mmHg, orthostatic hypotension - decrease of more than or equal to 20 mmHg for systolic BP, decrease of more than or equal to 10 mmHg for diastolic BP at screening.
  • Abnormal 24-h Holter of clinical relevance at screening.
  • Positive serology for antibodies (HIVAb), surface antigen (HBsAg) or virus antibodies (HCVAb).
  • and neutrophils count is \< the lower limit of normal range.
  • , aspartate aminotransferase, alkaline phosphatase and total > (ULN).
  • Any abnormal value of laboratory, vital signs, or physical examination, which may, in the opinion of the investigator interfere with the interpretation of the test results or cause a health risk for the subject.
  • Participation in an drug study within 2 months before entry into this study.
  • An employee or direct relative of the employee of the CRO or sponsor.
  • Any other condition that in the opinion of the investigator would interfere with the evaluation of the results or constitute a health risk for the subject.

Additional exclusion criteria for Part I and II:

  • An abnormal screening EEG.
  • A history of skin conditions or bad reactions after exposure to capsaicin or mustard oil.
  • Following intradermal injection of capsaicin (100 μg) at screening visit, the area of hyperalgesia was \< 10 cm2, or if the area of flare \< 10 cm2 at 15 min.

Additional exclusion criterion for Part II:

  • Use of nicotine-containing products within the previous 3 months.

The following additional exclusion criterion will be checked in Part I and II:

  • Inability to complete either Digital Symbol Substitution Test (DSST) (for Part I) or psychomotor test battery (for Part II).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    ODM-108 Part I

    Oral capsules dosage 0.2 - 240 mg once daily for one day

    Drug: ODM-108 Part I

  • Placebo comparator
    Placebo Part I

    Oral capsules given once daily for one day

    Drug: Placebo Part I

  • Experimental
    ODM-108 Part II

    Oral capsules 4 dose levels to be decided after Part 1 of the study. 1 - 4 times a day for 7 days

    Drug: ODM-108-Part II

  • Placebo comparator
    Placebo Part II

    Oral capsules 1 - 4 times per day for 7 days

    Drug: Placebo Part II

  • Experimental
    ODM-108 Part III

    Oral capsules 1-4 times daily for 7 to 10 days

    Drug: ODM-108 Part III

  • Active comparator
    Midazolam

    Single dose as a solution 3 days prior to the first dose of ODM-108 and on the last day of dosing with ODM-108

    Drug: Midazolam

Interventions

  • DrugODM-108 Part I

    Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo

  • DrugPlacebo Part I

    Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo

  • DrugODM-108-Part II

    Multiple escalating doses based on the results of Part 1. Either ODM-108 or placebo 1 - 4 times a day for 7 days

  • DrugPlacebo Part II

    Multiple escalating doses based on the results of Part 1. Either ODM-108 or placebo 1 - 4 times a day for 7 days

  • DrugODM-108 Part III

    Oral capsules 1 - 4 times daily for 7 to 10 days

  • DrugMidazolam

    Single dose as a solution 3 days prior to the first dose of ODM-108 and on the last day of dosing with ODM-108

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events in Part I and Part II.

    Clinically relevant changes from baseline of safety assessment

    Time frame: From screening up to 8 weeks

Secondary outcomes

  1. Part III (optional) Effect of ODM-108 on the activity of CYP3A4 (cytochrome P450 3A4) isoenzymes

    Measurement of biomarkers

    Time frame: Day 1 up to Day 11

  2. Part I Peak plasma concentration Cmax of ODM-108

    Cmax of ODM-108 after single dosing

    Time frame: Pre dose,15, 30, 45 mins, 1 h, 1 h 15, 1 h 30, 2 h, 2 h 30, 3 h, 4 h, 6 h, 8 h, 12h, 24 h, 48 h, 72 h, 96 h post dose at each dose level.

  3. Part I Metabolite screening in plasma and urine

    Metabolite screening in plasma and urine after single dosing

    Time frame: Pre-dose and 30 min, 1 h, 2 h, 4 h, 6 h, 12 h, 24 h and 48 h post dose at each dose level. Urine samples pre-dose and for 24 hours post dose at each dose level.

  4. Part I Sedation scores on Visual Analogue Scales

    Assessment of sedation by subject

    Time frame: Pre-dose, 2 h 30 min and 10 h post dose at each dose level

  5. Part I Cognitive function - Digital Symbol Substitution Test

    Assessment of cognitive function

    Time frame: Pre-dose, 2 h 30 min and 10 h post dose at each dose level

  6. Part I Intensity of spontaneous pain

    Intensity of spontaneous pain as assessed by a visual analogue scale

    Time frame: Screening and day 1 at 1, 5, 15, 30, 60 and 120 min after capsaicin injection.

  7. Part I Area of hyperalgesia

    Area of hyperalgesia quantified by a Von Frey monofilament

    Time frame: Screening and day 1 at 15, 30, 60 and 120 min after capsaicin injection.

  8. Part I area of flare response

    Area of flare response measured by Doppler blood flow scan

    Time frame: Screening and day 1 at baseline and 15, 30, 60 and 120 min after capsaicin injection.

  9. Part II Peak plasma concentration Cmax of ODM-108

    Cmax of ODM-108 after multiple dosing

    Time frame: Days 1 and 7: Pre-dose and 0.25, 0.5, 0.75,1,1.25,1.5, 2, 2.5, 3,4,6,8,12h post dose. Day 2-6 pre-dose, Day 7: 24, 48, 72 and 96h post dose

  10. Part II Peak plasma concentration Cmax of ODM-108 fed day 5 period 1

    Cmax of ODM-108 after multiple dosing

    Time frame: Days 1,5 and 7: Pre-dose and 0.25, 0.5, 0.75,1,1.25,1.5, 2, 2.5, 3,4,6,8,12h post dose. Day 2-6 pre-dose, Day 7: 24, 48, 72 and 96h post dose

  11. Part II Time to peak plasma concentration (tmax) of ODM-108

    tmax of ODM-108 after multiple dosing

    Time frame: Days 1 and 7: Pre-dose and 0.25, 0.5, 0.75,1,1.25,1.5, 2, 2.5, 3,4,6,8,12h post dose. Day 2-6 pre-dose, Day 7: 24, 48, 72 and 96h post dose

  12. Part II Time to peak plasma concentration (tmax) of ODM-108 fed day 5 period 1

    tmax of ODM-108 after multiple dosing

    Time frame: Days 1,5 and 7: Pre-dose and 0.25, 0.5, 0.75,1,1.25,1.5, 2, 2.5, 3,4,6,8,12h post dose. Day 2-6 pre-dose, Day 7: 24, 48, 72 and 96h post dose

  13. Part II Area under the plasma concentration versus time curve (AUC) of ODM-108.

    AUC of ODM-108 after multiple dosing

    Time frame: Days 1 and 7: Pre-dose and 0.25, 0.5, 0.75,1,1.25,1.5, 2, 2.5, 3,4,6,8,12h post dose. Day 2-6 pre-dose, Day 7: 24, 48, 72 and 96h post dose

  14. Part II Area under the plasma concentration versus time curve (AUC) of ODM-108 fed day 5 period 1

    AUC of ODM-108 after multiple dosing

    Time frame: Days 1,5 and 7: Pre-dose and 0.25, 0.5, 0.75,1,1.25,1.5, 2, 2.5, 3,4,6,8,12h post dose. Day 2-6 pre-dose, Day 7: 24, 48, 72 and 96h post dose

  15. Part II Elimination half-life of ODM-108

    Elimination half-life of ODM-108 after multiple dosing

    Time frame: Days 1 and 7: Pre-dose and 0.25, 0.5, 0.75,1,1.25,1.5, 2, 2.5, 3,4,6,8,12h post dose. Day 2-6 pre-dose, Day 7: 24, 48, 72 and 96h post dose

  16. Part II Elimination half-life of ODM-108- fed day 5 period 1

    Elimination half-life of ODM-108 after multiple dosing

    Time frame: Days 1,5 and 7: Pre-dose and 0.25, 0.5, 0.75,1,1.25,1.5, 2, 2.5, 3,4,6,8,12h post dose. Day 2-6 pre-dose, Day 7: 24, 48, 72 and 96h post dose

  17. Part II Binding of ODM-108 to proteins in plasma

    Assessment of binding of ODM-108 to proteins in plasma

    Time frame: Days 1 and 7 -1 h 30 min post dose

  18. Part II Metabolite screening in plasma and urine

    Metabolite screening in plasma and urine

    Time frame: Day 1 and 7 pre-dose and 30 min, 1 h, 2 h, 4 h, 6 h, 12 h, 24 h and 48 h post dose. Urine samples pre-dose and for 24 hours post dose at each dose level on days 1 and 7.

  19. Part II Sedation scores on Visual Analogue Scales

    Assessment of sedation by subject

    Time frame: Day 1 and day 6 pre-dose, 2 h 30 min, and 10 h post dose

  20. Part II Computerised psychomotor test battery measuring: attention, concentration, vigilance, memory, visual motor coordination and body sway.

    Assessment of psychomotor function

    Time frame: Days 1 and 6: pre-dose, approx. 2 h 30 min and 10 h after first daily ODM-108 dose

  21. Part II Intensity of spontaneous pain

    Assessed by numerical rating scale

    Time frame: Screening and day 5 at 1, 5, 15, 30, 60 and 120 min after capsaicin injection.

  22. Part II Area of hyperalgesia

    Area of hyperalgesia quantified by a Von Frey monofilament

    Time frame: Screening and day 5 at 5, 15, 30, 60 and 120 min after capsaicin injection.

  23. Part II Cutaneous blood flow and area of flare response

    Pain assessments

    Time frame: Screening and day 5 pre -dose and 5, 15, 30, 60 and 120 min after capsaicin injection.

  24. Part II Intensity of spontaneous pain

    Intensity of spontaneous pain as assessed by a visual analogue scale

    Time frame: Screening and day 7 at 1, 5, 15, 30, 60 and 120 min after mustard oil challenge.

  25. Part II Area of hyperalgesia

    Area of hyperalgesia quantified by a Von Frey monofilament

    Time frame: Screening and day 7 at 5, 15, 30, 60 and 120 min after mustard oil challenge.

  26. Part II Area of flare response

    Area of flare response measured by Doppler blood flow scan

    Time frame: Screening and day 7 baseline and 5, 15, 30, 60 and 120 min after mustard oil challenge.

  27. Part III (optional) Peak plasma concentration Cmax of midazolam

    Cmax of midazolam

    Time frame: day 1 and day 10 or 13

  28. Part III (optional) Time to peak plasma concentration (tmax) of midazolam

    tmax of midazolam

    Time frame: day 1 and day 10 or 13

  29. Part III (optional) Area under the plasma concentration versus time curve (AUC) of midazolam.

    AUC of midazolam

    Time frame: day 1 and day 10 or 13 (

  30. Part III (optional) ODM-108 levels in cerebrospinal fluid

    Assessment of levels of ODM 108 in cerebrospinal fluid

    Time frame: day 9

  31. Part I Time to peak plasma concentration (tmax) of ODM-108

    tmax of ODM-108 after single dosing

    Time frame: Pre dose,15, 30, 45 mins, 1 h, 1 h 15,1 h 30, 2 h, 2 h 30, 3 h, 4 h, 6 h, 8 h, 12h, 24 h, 48 h, 72 h, 96 h post dose at each dose level.

  32. Part I Area under the plasma concentration versus time curve (AUC) of ODM-108.

    AUC of ODM-108 after single dosing

    Time frame: Pre dose,15, 30, 45 mins, 1 h, 1 h 15,1 h 30, 2 h, 2 h 30, 3 h, 4 h, 6 h, 8 h, 12h, 24 h, 48 h, 72 h, 96 h post dose at each dose level.

  33. Part I Elimination half-life of ODM-108

    Elimination half-life of ODM-108 after single dosing

    Time frame: Pre dose,15, 30, 45 mins, 1 h, 1 h 15,1 h 30, 2 h, 2 h 30, 3 h, 4 h, 6 h, 8 h, 12h, 24 h, 48 h, 72 h, 96 h post dose at each dose level.

07

Study locations

1 site
  • PRA Health Sciences
    Zuidlaren, 9471GP, Netherlands
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2015 to primary completion in Apr 2016, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2015
First posted
May 4, 2015
StartActual
Apr 14, 2015
Primary completionActual
Apr 22, 2016
CompletionActual
Apr 22, 2016
Last update
Jul 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02432664
Collaborators
PRA Health Sciences
Responsible party
Sponsor
First posted
May 4, 2015
Start date
Apr 14, 2015
Primary completion
Apr 22, 2016
Completion
Apr 22, 2016
Last update
Jul 2, 2017

Study contacts

Sjoerd van Marle, M.D
principal investigator · PRA Health Sciences
Sara Haworth
study director · Orion Corporation, Orion Pharma

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion